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Heartland virus (HRTV) is a recently described phlebovi-
rus initially isolated in 2009 from 2 humans who had leu-
kopenia and thrombocytopenia. Serologic assessment of 
domestic and wild animal populations near the residence 
of 1 of these persons showed high exposure rates to rac-
coons, white-tailed deer, and horses. To our knowledge, 
no laboratory-based assessments of viremic potential of 
animals infected with HRTV have been performed. We 
experimentally inoculated several vertebrates (raccoons, 
goats, chickens, rabbits, hamsters, C57BL/6 mice, and 
interferon-α/β/γ receptor–deficient [Ag129]) mice with 
this virus. All animals showed immune responses against 
HRTV after primary or secondary exposure. However, 
neutralizing antibody responses were limited. Only Ag129 
mice showed detectable viremia and associated illness 
and death, which were dose dependent. Ag129 mice also 
showed development of mean peak viral antibody titers >8 
log10 PFU/mL, hemorrhagic hepatic lesions, splenomegaly, 
and large amounts of HRTV antigen in mononuclear cells 
and hematopoietic cells in the spleen.
Heartland virus (HRTV) is a novel bunyavirus (fam-ily Bunyaviridae, genus Phlebovirus) first identified 
in the United States in 2 persons with thrombocytopenia/
leukopenia in Missouri in 2009 (1). The virus has subse-
quently been isolated from nymphal Amblyomma ameri-
canum ticks collected at sites adjacent to the residences 
of the index case-patients (2). High seroprevalence rates 
for HRTV have been reported in northern raccoons (Pro-
cyon lotor), white-tailed deer (Odocoileus virginianus), 
and horses sampled near the residences of human case-
patients (3). Additional serosurveillance in wildlife has 
demonstrated wide-ranging antibody prevalence to HRTV 
across the geographic host range distribution of A. ameri-
canum ticks (4).
Genetically, HRTV is most closely related to severe 
fever with thrombocytopenia syndrome virus (SFTSV) (1), 
a tickborne virus in Asia that causes high fever, thrombo-
cytopenia, leukopenia, gastrointestinal disorders, central 
nervous system involvement, disseminated intravascular 
coagulopathy; and multiorgan dysfunction. Infection with 
this virus shows a case-fatality rate of ≈12% in humans 
(5,6). Severe disease progression of patients infected with 
SFTSV has further been associated with increased cyto-
kine and chemokine responses (7) and increased viremias 
throughout the course of disease (6). Infection of rhesus 
macaques with SFTSV caused mild human disease syn-
dromes similar to those in humans, including thrombocy-
topenia, leukopenia, and increased levels of hepatic and 
cardiac enzymes (8).
Unlike SFTSV, which has been associated with thou-
sands of cases of symptomatic human disease in China (5) 
and South Korea (9), only  8 diagnosed human cases of 
HRTV infection have been reported in the United States, 
and 1 death in 2013 (10). Of those patients, 7 were from 
Missouri and 1 from Tennessee (this patient died), which 
indicated the continued presence of the virus over the 
course of several years and over a wide geographic range 
(11). Similar to that described for SFTSV, patients infect-
ed with HRTV commonly have fever, fatigue, anorexia, 
thrombocytopenia, leukopenia, and increased levels of he-
patic enzymes (11).
With the recent discovery of SFTSV, HRTV, and 
other novel phleboviral agents in recent years (12–14), it 
is apparent that tickborne phleboviruses have been largely 
underrecognized as potential human disease agents. The 
vertebrate host range associations for SFTSV have been 
poorly described and have not been addressed for HRTV 
by experimental animal inoculation studies.
Given the serologic evidence that northern raccoons 
are commonly exposed to HRTV across the central and 
eastern United States (4) and near the residence of a human 
index case-patient (3), we performed experimental inocula-
tions of raccoons with HRTV. In addition, on the basis of 
results of goat serosurveillance for SFTSV in China (15) 
and experimental infections (16), we performed experi-
mental inoculation of goats with HRTV. We also assessed 
animal models (chickens, rabbits, hamsters, and mice) for 
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host competence for HRTV to identify host range restric-
tions of the virus and establish a potential model for vire-
mic blood feeding for subsequent tick infections.
Materials and Methods
Viruses and Animal Models
We used an isolate of HRTV (Mo4) obtained from serum 
of an acutely ill human patient in the fall of 2009 for ex-
perimental infections and plaque reduction neutralization 
tests (PRNTs). The isolate was passaged once on Vero E6 
cells (African green monkey kidney cell line). Lone Star 
virus (LSV) strain 2229 was used as a control virus for in-
traperitoneal and intracranial inoculation of CD-1 mice. All 
animal models (including strain, age, inoculation route, and 
dose inoculated) assessed for host competence for HRTV 
are shown in Table 1. New Zealand white rabbits, chickens, 
Syrian golden hamsters, C57BL/6 mice, and CD-1 mice 
were obtained from Charles River Laboratories (Wilm-
ington, MA, USA) and housed at the Centers for Disease 
Control and Prevention (Fort Collins, CO, USA) in Animal 
Biosafety Level 3 (ABSL 3) conditions. Ag129 mice (α/β/γ 
receptor knockout) (17) were originally obtained from B 
& K Universal (Hull, UK) and bred in house. The receptor 
knockout genotype of the Ag129 mouse breeding line was 
confirmed by genetic PCR markers generated from tail snip 
tissues from 10 mice (Transnetyx, Cordova, TN, USA).
Boer goats were obtained from a private vendor and 
housed in the Colorado State University Animal Disease 
ABSL 3 Laboratory. Six raccoons were caught in the wild 
in Larimer County, Colorado, and housed in a US Depart-
ment of Agriculture facility for several months before be-
ing transferred to the Animal Disease ABSL 3 Laboratory 
at Colorado State University for experimental inoculation. 
Raccoon serum samples were screened for neutralizing 
antibodies against HRTV/phlebovirus as described (3) 
and in this report. All animal handling, trapping, and care 
was in compliance with approved Institutional Animal 
Care and Use Committee protocols under the oversight 
of attending veterinarians. At arrival in the laboratory, all 
animals were housed for a minimum of 3 days for accli-
matization before inoculation.
Experimental Inoculations
We inoculated animals with 100–105 PFU by subcutane-
ous, intracranial, or intraperitoneal routes (Table 1). Whole 
blood was collected from individual hamsters, rabbits, 
chickens and goats daily during 1–7 days postinoculation 
(dpi), groups of 3 raccoons on alternating days 1–8 dpi, 
and 3 groups of 5 or 6 C57BL/6 and Ag129 mice every 
third day 1–9 dpi. Ag129 mice were divided into 5 dos-
age groups of 15 mice (100–104 PFU) (Table 1). At 28 dpi, 
animals from all groups (except raccoons) were bled and 
then given booster inoculations with 104 PFU of HRTV 
and analyzed through 42 dpi, at which point the animals 
were bled and euthanized. Terminal blood samples were 
obtained from mice by cardiac bleed under deep isoflurane 
anesthesia just before euthanasia. Two Ag129 mice (102 
PFU dose group) were terminally bled at 4 days postsec-
ondary challenge, and spleens were harvested for produc-
tion of monoclonal antibodies (MAbs) as described (18).
Raccoons were anesthetized with a ketamine:xylazine 
cocktail (15–20 mg/kg:3–4 mg/kg) (3) given by intramus-
cular inoculation before sampling, and mice and hamsters 
were anesthetized in an isoflurane chamber before serum 
sampling. Rabbits, chickens, and goats were manually re-
strained appropriately for sample collection without use of 
anesthetics. Whole blood was collected from peripheral 
saphenous, cheek, or tail veins (mouse and hamster); ear 
(rabbit); or jugular (chicken and raccoon). Samples were 
centrifuged, and serum samples were frozen for subse-
quent virologic or serologic evaluation. Relative neuro-
invasive and neurovirulence phenotypes for HRTV were 
compared with that for LSV strain 2229 by intraperitoneal 
and intracranial inoculation, respectively. Isoflurane-anes-
thetized suckling (2 days old) and weanling (17 days old)  
 
 
Table 1. Experimental inoculation of vertebrate hosts with Heartland virus* 
Experimental animal model Strain No.  Age, d/sex Inoculum dose, PFU Route of inoculation 
Mouse C57BL/6 15 21/ F 104 ip 
Mouse Ag129 15 21/M and F 104 ip 
Mouse Ag129 15 21/M and F 103 ip 
Mouse Ag129 15 21/M and F 102 ip 
Mouse Ag129 15 21/M and F 101 ip 
Mouse Ag129 15 21/M and F 100 ip 
Mouse† CD-1 10 2 103 ic 
Mouse† CD-1 10 17 103 ip 
Chicken Leghorn 3 Adult/F 104 sc 
Hamster Syrian golden 5 21/F 104 sc 
Goat Boer 2 Adult/M and F 104 sc 
Rabbit New Zealand white 3 Adult/F 104 sc 
Raccoon Wild-caught 6 Adult/M and F 104 sc 
*Ag129, interferon-// receptor–deficient; ic, intracranial; ip, intraperitoneal; sc, subcutaneous. 
†CD-1 mice were also inoculated similarly with Lone Star virus (same dose and route as for Heartland virus). 
 
 Vertebrate Host Susceptibility to Heartland Virus
CD-1 mice (n = 10) were inoculated with a 20 µL of sterile 
phosphate-buffered saline (PBS) suspension of 103 PFU of 
either virus. A group inoculated with minimal essential me-
dium was included as an inoculation control for both routes 
of inoculation.
Serologic Testing
HRTV neutralizing and total immune reactive antibodies 
were quantified by using a 70% PRNT (PRNT70) (18) and 
ELISA, respectively. For PRNTs, serum samples were 
heat-inactivated at 56°C for 30 min, and 2-fold serially 
diluted serum samples were mixed with an equal volume 
of virus suspension. Plaques were enumerated through 
10 dpi, and 70% neutralization endpoints were calculated 
on the basis of comparison with serum negative controls 
as described (3).
ELISAs were performed in 96-well microtiter plates 
(Immulon 2HB; Thermo Lab Systems, Franklin, MA, 
USA). Plate wells were coated with purified virus (0.06 µg/
well) in buffer (50 mmol/L sodium carbonate, 50 mmol/L 
sodium bicarbonate, pH 9.6) and incubated at 4°C over-
night (18). Plates were washed 5 times with a PBS/0.1% 
Tween wash buffer, and nonspecific binding sites were 
blocked with Starting Block (Pierce, Dallas, TX, USA) 
(100 µL/well). Serum samples were added in serial dilu-
tions in PBS (50 µL/well) and incubated at 37°C for 1 h. 
Plates were washed 5 times before addition of the species-
appropriate horseradish peroxidase conjugate (50 µL/well), 
diluted 1:5,000 in PBS. After an incubation period of 1 h 
at 37°C, plates were washed and enhanced K-Blue TMB 
(3,3′,5,5′ tetramethylbenzidine) substrate (Neogen, Lex-
ington, KY, USA) was added to each well (100 µL/well). 
The plates were incubated in the dark at room temperature 
for 10 min. Optical density (OD) was read on an automatic 
plate reader at 450 nm. Endpoints were determined as an 
OD reading on duplicate samples that was at least twice 
that of the average OD for control serum samples. Titers 
were expressed as the geometric mean of the reciprocal of 
the endpoints.
Immunohistochemical Analysis
HRTV-inoculated Ag129 mice with signs of disease were 
subjected to necropsy. Spleen, liver, and kidney tissues 
were removed, fixed in 10% neutral-buffered formalin, 
and processed by using routine methods (10). Immuno-
histochemical analysis using rabbit polyclonal antisera 
against HRTV nucleocapsid (N) protein and an immu-
no-alkaline phosphatase detection system with Fast Red 
Chromogen (Biocare Medical, Concord, CA, USA) was 
used as described (1).
Results
Viremia, Death, and Clinical Assessment
Serum samples from chickens, raccoons, goats, rabbits, and 
hamsters obtained during 1–7 dpi did not show detectable 
HRTV viremia (Table 2). Despite the previous finding that 
SFTSV replicates to detectable levels in serum and results 
in pathologic changes in spleens of immunocompetent 
C57BL/6 mice (19), viremia was not detected in any serum 
samples from this strain of mice inoculated with HRTV. 
No infection-associated deaths or clinical signs of illness 
were observed throughout the course of the infection in any 
of inoculated animals.
In contrast, 100% of CD-1 mice inoculated intracra-
nially with LSV died within 6 dpi. However, illness or 
death were not observed in mice inoculated with minimal 
essential medium or HRTV. Similar to intraperitoneally in-
oculated C57BL/6 mice, intraperitoneally inoculated CD-1 
mice showed no signs of illness or death. However, Ag129 
mice showed virus dose-dependent death. Deaths were ob-
served in the group inoculated with 104 PFU; the first signs 
of illness appeared on 4 dpi and death occurred on 5 dpi 
(Figure 1, panel A). Groups inoculated with 103, 102, 101, or 
100 PFU had mortality rates of 85%, 83%, 80%, and 20%, 
respectively. Average survival time was inversely propor-
tional to the inoculation dosage. Mean ± SD survival time 
ranged from 4.1 ± 0.4 d for the 104 PFU dose group to 19.4 
± 4.2 d for the 101 PFU dose group (Figure 1, panel A).  
 
 
Table 2. Viremia and antibody responses of animals experimentally inoculated with Heartland virus* 
Animal 
Inoculum dose, 
PFU 
Mean peak 
titer† dpi 
Mean ELISA 
titer‡ 
ELISA positive, 
no. (%) 
Mean PRNT70 
titer‡ 
PRNT70 
positive, no. (%) 
Mouse (C57BL/6) 104 <1.5 42§ 4.4 (0.6) 15 (94) 0.7 (0.6) 10 (63) 
Chicken 104 <1.5 14 NT NA ND 0 
Chicken 104 NA 42§ 3.0 (0.2) 3 (100) ND 0 
Hamster 104 <1.5 42§ 4.3 (0.5) 4 (100) 1.3 (0.4) 5 (100) 
Goat 105 <1.5 28 NT NA 1.0 2 (100) 
Goat 105 NA 42§ 3.0 2 (100) 1.3 2 (100) 
Rabbit 104 <1.5 14 NT NA ND 0 
Rabbit 104 NA 42§    4.1 3 (100) 1.2 (0.2) 3 (100) 
Raccoon 104 <1.5 42 NT NA 0.4 (0.6) 2 (33) 
*Bold indicates initial (not given a booster immunization) sampling of a pair of animals that were later given a booster immunization. dpi, day 
postinoculation; NA, not assessed; ND, not detected (no titer <1:10 for any animal); NT, not tested; PRNT70, 70% plaque reduction neutralization test. 
†Detection limit was 1.5 log10 PFU/mL. 
‡log10 reciprocal titer (SD).  
§Animals were given booster inoculations with 104 PFU of Heartland virus at 28 dpi. 
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Mean ± SD time of death also showed prolonged survival 
rates with lower inoculation doses when survivors were 
omitted from the analyses: 4.1 ± 0.4 d (104), 5.1 ± 0.3 d 
(103), 7.7 ± 2.2 d (102), 9.1 ± 3.7 d (101), and 9 ± 1.4 d (100) 
(Figure 1, panel A). We calculated a 50% lethal dose of 9 
PFU by using linear regression analysis of the mortality 
rate at various viral dilutions (R2 = 0.84).
Viremia titers were also dose dependent; peak titers 
were highest in the 104 PFU group and lowest in the 100 
PFU group (Table 3). Onset of viremia in most of the in-
oculation groups was at 2 dpi or 3 dpi, and the 104 PFU 
inoculation group had the highest initial daily viremia titer 
at 2 dpi (2.5 ± 0.5 log10 PFU/mL serum) and the highest 
mean daily peak viremias by 5 dpi (8 log10 PFU/mL serum) 
(Figure 1, panel B). However, 3 of the mice had viremias at 
5 dpi >9 log10 PFU/mL serum. Only 5 of 15 Ag129 mice in 
the 100 inoculation group had detectable viremias; highest 
detectable titer was 4 log10 PFU/mL serum. Clinical signs 
in Ag129 mice included hunched back, ruffled fur, muco-
purulent ocular discharge, and hematochezia. Mice that had 
these signs were euthanized and subjected to necropsy for 
gross and histopathologic analysis of lesions.
Serologic Analysis
All animals except raccoons received booster inocula-
tions at 28 dpi with 104 PFU of HRTV. HRTV neutralizing 
antibodies were not detected in chickens through 42 dpi 
after booster inoculation, but ELISA titers were evident 
(3.0 log10) (Table 2). Low, but detectable, PRNT70 titers (1 
log10–1.3 log10) were observed in rabbits given booster in-
oculations; ELISA titers were <4.1 log10. All hamsters giv-
en booster inoculations had neutralizing titers (1 log10–1.9 
log10) and ELISA titers (4.3 log10). Despite the high HRTV 
neutralizing antibody prevalence and magnitude of the im-
mune response identified in the field for raccoons, 0 of 6 
experimentally inoculated raccoons had detectable viremia, 
and only 2 had PRNT70 titers (1 log10 and 1.3 log10). ELISA 
titers for raccoons were not assessed because of a lack of 
appropriate species-associated conjugate. The 2 goats had 
low (1.3 log10) neutralizing immune responses after booster 
inoculation, and ELISA titers of 3.0 log10 were detected. 
C57BL/6 mice responded to infection with no detectable 
(0.7 log10) titers detected by PRNT and 4.4 log10 titers de-
tected by ELISA (Table 2).
Serologic Response and Challenge of  
Surviving Ag129 Mice
Eighteen (24%) of 75 Ag129 mice survived the initial in-
oculation with HRTV (11 from the 100 PFU group, 3 from 
the 101 PFU group, 2 from the 102 PFU group, and 2 from 
the 103 PFU group). The 2 surviving Ag129 mice from the 
103 PFU group were terminally bled for immune responses 
at 21 dpi. One mouse had an ELISA titer of 1:364,500, and 
the other mouse had no detectable reactivity (titer <1:500) 
(Table 3). The 2 Ag129 mice that survived the 102 PFU 
inoculation dose had ELISA titers of 1:121,500 and <1:500 
at 28 dpi. These mice were given booster inoculations with 
104 PFU of HRTV, and spleens harvested 4 days later (32 
dpi) for detection of splenocyte fusions and myeloma cells 
for MAb development as described (18). At 32 dpi (4 days 
post-HRTV booster inoculation/challenge), neutralizing 
responses were detected in both mice (1.9 log10 and 2.5 
log10 reciprocal titers), and no serum viremia or virus was 
detected in the spleens.
Figure 1. Dose response of Heartland virus (HRTV)–infected interferon α/β/γ receptor–deficient (Ag129) mice. Mice of either sex  
were inoculated with 104–10° PFU of HRTV/0.1 mL of inoculum. Mice were observed daily for death through day postinoculation 24. 
A) Percentage survival. B) Dose-associated HRTV viremias determined by plaque assays on Vero E6 cells. Different groups of 5 mice 
inoculated with the same dose of HRTV were bled every third day. Thus, a decrease in viremia was observed for the 102 PFU dose 
inoculum group days postinoculation 5 and 6. Error bars indicate SD.
Only 1 of the 3 Ag129 mice that survived initial chal-
lenge with HRTV at a dose of 101 PFU showed immune 
reactivity to HRTV antigen by ELISA (titer 1:121,500) 
at 28 dpi. Similarly, 1 of 11 surviving Ag129 mice from 
the 100 PFU dose group showed HRTV immune reactivity 
(titer 1:1,500) (Table 3) at 28 dpi. An HRTV neutralizing 
titer of 1:10 was identified in the 28 dpi serum sample from 
the ELISA-positive surviving mouse from the 100 PFU 
inoculation group. In addition, the surviving mouse with 
the higher ELISA titer from the 101 PFU dose group did 
not have a detectable PRNT70 titer, although neutralizing 
titers were observed at lower thresholds. These 14 surviv-
ing mice were challenged with 104 PFU of HRTV at 28 
dpi and observed for an additional 14 days through 42 dpi. 
Eight (57%) of the 14 secondarily challenged Ag129 mice 
survived through 42 dpi (2/3 in the 101 PFU dose group and 
6/11 in the 100 PFU dose group), which indicated a protec-
tive immune response. However, only 3 of the 8 (1 in 101 
PFU dose group and 2 in 100 PFU dose group) surviving 
mice had detectable neutralizing antibodies against HRTV, 
and the mean ± PRNT70 titers were only 1.9 and 1.5 ± 0.6 
for the 2 dose groups, respectively (Table 3).
Pathologic Analysis
At necropsy, hamsters, chickens, rabbits, raccoons, goats, 
and C57BL/6 mice were in good physical condition and 
none showed gross pathologic lesions associated with 
HRTV infection. In contrast, Ag129 mice had clear signs 
of illness (Figure 2, panel A), including hunched posture, 
ruffled fur, rectal hemorrhage, weight loss, and conjuncti-
vitis. Euthanized Ag129 mice had grossly enlarged, pale 
spleens, hepatic hemorrhage, enlarged gall bladders, and 
excess peritoneal fluid (Figure 2, panel B). Hematoxylin 
and eosin–stained sections of Ag129 spleen and liver and 
tissues showed reactive white pulp (Figure 2, panel C), 
abundant apoptotic debris and hepatic sinusoids (Figure 
2, panel D), and increased numbers of mononuclear cells. 
Immunohistochemical analysis showed abundant HRTV 
antigen was observed diffusely within splenic mononuclear 
cells (Figure 2, panel C), hepatic sinusoidal (Kupffer) cells 
(Figure 2, panel D), and renal interstitial mononuclear cells 
(Figure 2, panel E).
Discussion
HRTV is a novel bunyavirus known to cause serious dis-
ease in a small number of humans. Serologic surveillance 
and isolation from A. americanum tick nymphs suggested 
that HRTV circulates in an enzootic cycle and spills over 
into humans when they are exposed to infected ticks (2,3). 
However, in the animal models we present in this study, 
no evidence of replicative infection in any of the wildlife 
or outbred animals tested was observed, and viremia, ill-
ness, and death could only be induced in type I and type 
II interferon-receptor knockout mice. Likewise, although 
SFTSV has been found to cause viremia and pathologic 
manifestations, such as leukopenia and thrombocytopenia 
in C57BL/6 mice, which is consistent with human patho-
logic changes, these mice did not show any clinical signs 
of disease, and evidence of viral replication was limited to 
the spleen (19).
However, all interferon α/β receptor knockout mice 
(IFNAR −/−) inoculated with SFTSV died within 3–4 
dpi and showed marked SFTSV antigen expression and 
increased viremia profiles than did wild-type mice of the 
same genetic background (19,20), which is consistent with 
our results for Ag129 mice experimentally inoculated with 
HTRV (20). Furthermore, the protective role of the inter-
feron response has also been demonstrated by depleting 
interferon in age-resistant C57BL/6 mice infected with an-
other phlebovirus (Punta Toro virus) (21). These data and 
the experimental inoculation data in our study indicate that 
the interferon response is critical for controlling pathologic 
changes of mice infected with phleboviruses.
Similar to pathologic changes reported for SFTSV in-
fection in C57BL/6 mice (19) and IFNAR knockout mice 
(20), viremia and major pathologic changes developed in 
 
 
 
Table 3. Viremia and antibody responses of interferon-// receptor–deficient mice experimentally inoculated with Heartland virus* 
Inoculum dose, PFU dpi Mean peak titer† 
Mean ELISA 
titer 
ELISA positive, 
no. (%) 
Mean PRNT70 
titer‡ 
PRNT70 positive, 
no. (%) 
104 NA 8 (1.0) NA  NA  
104 NA  NA  NA  
103 21 6.6 (1.2) 4.1 (2.0) 1 (50) NT  
102 28 5.3 (2.3) 3.9 (1.7) 1 (50) NT NT 
102 32  NT  2.2 (0.4) 2(100)§ 
101 28 4.6 (2.1) 3.5 (1.4) 1 (33) 1.5 (0.6) ND 
101 42  NT  1.3 (0.5) 1 (33) 
100 28 3.4 (2.2) 2.7 (1.4) 1 (9) 1 1 (9) 
100 42  NT  1.5 (0.6) 2 (33) 
*Bold indicates initial (not given a booster immunization) sampling of a pair of animals that were later given a booster immunization. dpi, day 
postinoculation; NA, not applicable because uniform deaths were observed; ND, not detected; NT, not tested; PRNT70, 70% plaque reduction 
neutralization test; , not assessed for titer. 
†Peak titers (log10 PFU/mL of serum) (SD). Detection limit was 1.5 log10 PFU/mL. 
‡log10 reciprocal titer (SD). 
§Tested at 4 d postchallenge. 
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Ag129 mice inoculated with HTRV, which is consistent 
with platelet depletion and subsequent thrombocytopenia. 
Histopathologic analysis showed a tropism for mono-
nuclear cells, as shown by detection of HRTV N protein 
in splenic mononuclear cells, Kupffer cells, and intersti-
tial mononuclear cells within the kidney. Future studies 
are needed to directly assess the capacity of the Ag129 
mouse model to recapitulate leukopenia and thrombocyto-
penia manifestations observed in human disease progres-
sion and the subsequent role of splenic macrophages with 
platelet depletion (19).
Nine hydridomas expressing HRTV MAbs derived 
from HRTV-inoculated Ag129 splenocyte fusions de-
scribed in this report have been characterized. All of them 
were found to be nonneutralizing and reactive to linear 
epitopes of the HRTV N protein (18). These results are 
not surprising because phlebovirus N protein is the most 
abundant protein in the virion and in virus-infected cells 
(22–24). Similarly, most MAbs against SFTSV are also 
specific for N protein and nonneutralizing (25,26). Because 
the humoral response to N protein occurs early in infec-
tion, this protein is used as a diagnostic antigen (22,27–30). 
The presence of N protein-targeted humoral responses, 
measured by ELISA titers, in C57BL/6 and Ag129 mice 
with low neutralizing activity supports the hypothesis that 
the N protein could serve as an immunologic decoy. Poor 
humoral neutralizing response of infected hosts to anoth-
er bunyavirus, Crimean-Congo hemorrhagic fever virus 
(genus Nairovirus), has been associated with enhanced 
strain-specific virulence in humans (31). Crimean-Congo 
hemorrhagic fever virus is rapidly cleared in immunocom-
petent mice, replicates to high titer, and induces pathologic 
changes and thrombocytopenia in IFNAR mice, similar to 
the disparate results obtained in this experiment between 
C57BL/6 and Ag129 mice (22,27–30).
The lack of proper receptors, such as dendritic cell–
specific intercellular adhesion molecule 3–grabbing 
nonintegrin (DC-SIGN) on Vero cells, used in neutral-
ization assays could also explain the low neutralization 
titers we observed. When compared with cells that were 
modified to express DC-SIGN, Mukherjee et al. found 
that neutralization titers to dengue virus were found to 
be increased (32). DC-SIGN has been shown to serve as 
a receptor for attachment and endocytosis in phleboviral 
infections, including those with SFTSV, Rift Valley fe-
ver virus, and Uukuniemi virus (33,34). The extremely 
Figure 2. Pathologic changes 
associated with infection of 
interferon-α/β/γ receptor–
deficient (Ag129) mice with 
Heartland virus (HRTV). A) 
Mouse showing typical clinical 
signs of HRTV infection 
(ruffled fur, hunched posture, 
and squinting eyes). B) 
Dissected mouse showing an 
enlarged pale spleen (arrow). 
C–E) Hematoxylin and eosin 
staining (left panels) and 
immunohistochemical staining 
(right panels) for HRTV 
nucleocapsid protein of spleen 
(C), liver (D), and kidney (E) 
of Ag129 mice at 5–7 days 
postinoculation with 104 PFU 
virus. Original magnifications: C, 
×100; D, ×50; E, ×100.
low level of detected neutralizing antibodies in Ag129 
mice that subsequently survived challenge with 1,000 
50% lethal doses of HRTV indicates that neutralizing 
antibody assays are not congruent with humoral protec-
tion levels or that cell-mediated immune responses af-
ford considerable protection.
The vertebrate host competence studies reported here 
also demonstrate the potential host specificity that could 
have evolved over long periods concomitant with diversi-
fication of HRTV from other phleboviruses. Our findings 
do not exclude the potential role of multiple vertebrate 
host(s) for maintenance of HRTV; several key animals, 
such as horses and white-tailed deer, for which there is 
serologic evidence of field exposures and tick associa-
tions, have yet to be assessed for HRTV host competence. 
Nymphal A. americanum ticks, from which HRTV has 
been isolated (2), are known to be catholic feeders, and 
white-tailed deer may be a major host for the nymphal 
stage of these ticks (35). HRTV could potentially circu-
late without the need for actual replication in the verte-
brate host through direct tick-to-tick transmission while 
co-feeding nearby on a vertebrate host, as described for 
the orthomyxovirus, Thogoto virus (36).
The role of direct tick transmission of virus to the ver-
tebrate host should be considered because it is related to 
modulation of the host innate immune response and the 
potential establishment of a permissive environment for 
HRTV replication. Previous studies have demonstrated that 
salivary transmission of Thogoto virus has potentiated the 
antagonism of interferon-induced Mx1 antiviral activity 
and resulted in successful transmission of co-feeding ticks 
on a mouse strain for which parenteral inoculation was un-
successful (37). Salivary transmission by ticks could be a 
major factor because of immunomodulatory effects of the 
saliva (38,39) or differential immune signaling because of 
specific lectins incorporated onto viral structural proteins, 
which result from growth in arthropod cells (40). This 
modulation by salivary components could affect initial 
replication in skin dendritic cells and result in subsequent 
development of viremias and neutralizing titers in field-
collected animals. Repeated exposure of attached ticks 
salivating virus over prolonged periods could be sufficient 
for neutralization titers to be manifested in the absence of 
viral replication.
In conclusion, this study provides an assessment of the 
relative susceptibility of several vertebrate hosts to paren-
teral infection with HRTV and a preliminary assessment of 
a potential model for HRTV-associated disease pathology 
in humans. Ag129 mice could be used as a source for estab-
lishing direct tick infection or as a transmission model for 
infected A. americanum ticks for subsequent assessment of 
these and alternative natural vertebrate host candidates for 
HRTV transmission.
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